United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Ticker
$UTHR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,305
ISIN
US91307C1027
Website
UTHR Metrics
BasicAdvanced
$13B
11.63
$25.10
0.53
-
Price and volume
Market cap
$13B
Beta
0.53
52-week high
$403.35
52-week low
$266.98
Average daily volume
616K
Financial strength
Current ratio
5.461
Quick ratio
5.05
Total debt to equity
2.938
Interest coverage (TTM)
41.39%
Profitability
EBITDA (TTM)
1,554.9
Gross margin (TTM)
89.00%
Net profit margin (TTM)
40.44%
Operating margin (TTM)
49.35%
Effective tax rate (TTM)
22.58%
Revenue per employee (TTM)
$2,290,000
Management effectiveness
Return on assets (TTM)
12.94%
Return on equity (TTM)
19.94%
Valuation
Price to earnings (TTM)
11.632
Price to revenue (TTM)
4.357
Price to book
1.93
Price to tangible book (TTM)
1.97
Price to free cash flow (TTM)
11.559
Free cash flow yield (TTM)
8.65%
Free cash flow per share (TTM)
2,526.25%
Growth
Revenue change (TTM)
19.85%
Earnings per share change (TTM)
18.87%
3-year revenue growth (CAGR)
19.19%
10-year revenue growth (CAGR)
8.48%
3-year earnings per share growth (CAGR)
20.26%
10-year earnings per share growth (CAGR)
21.46%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
Bulls say / Bears say
United Therapeutics reported a 17% year-over-year revenue increase in Q1 2025, reaching $794.4 million, indicating strong financial performance. (biospace.com)
The company is advancing its UKidney program, with FDA clearance to commence the first human clinical trial of a xeno-organ product, potentially revolutionizing organ transplantation. (sec.gov)
United Therapeutics was named to the '100 Best Companies to Work For' in 2025 by Fortune, reflecting a strong corporate culture that can attract and retain top talent. (stocktitan.net)
The impending launch of Liquidia's Yutrepia after May 2025 poses a direct competitive threat to United Therapeutics' key Tyvaso franchise. (panabee.com)
United Therapeutics accrued a $71.1 million liability related to ongoing litigation with Sandoz Inc., which could impact financial stability. (tradingview.com)
The company's significant investments in high-risk organ manufacturing projects, with R&D expenses up 18% to $481 million, may not yield expected returns. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
UTHR News
AllArticlesVideos
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
Business Wire·5 days ago
The Top 3 Stock Picks at the World's Greatest Hedge Fund
MarketBeat·3 months ago
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $13B as of July 21, 2025.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 11.63 as of July 21, 2025.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of July 21, 2025.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.